Influenza Coinfection: Be(a)ware of Invasive Aspergillosis

Authors:

Abstract
To the Editor—Uyeki et al [ 1] recently published the 2018 update of the clinical practice guideline regarding the diagnosis, chemoprophylaxis, and institutional outbreak management of seasonal influenza. The document discusses several aspects related to influenza, including the occurrence and management of coinfections. Although the guideline is primarily aimed to guide US clinicians, the recommendations are implemented in many countries worldwide. We therefore draw attention to recent observations regarding invasive aspergillosis as coinfection in patients with severe influenza in some regions [ 2]. Although the guideline states that invasive fungal coinfection is rare in adults with influenza, 3 cohort studies performed in Belgium and the Netherlands showed that influenza-associated aspergillosis (IAA) had occurred in 16%–23% of influenza patients in the intensive care unit (ICU) [ 3–5]. The largest cohort study investigated 7 ICUs over a period of 7 flu seasons and showed that influenza and the use of corticosteroids before ICU admission were independent risk factors for IAA [ 5]. IAA was observed in every flu season and both in patients with influenza A and influenza B pneumonia [ 5]. The mortality of severe influenza patients with IAA was 51% compared with 28% in those without IAA [ 5]. Furthermore, IAA coinfection occurred in patients with a broad variety of underlying conditions, and up to 30% of patients had been previously healthy [ 4, 5].

This publication has 10 references indexed in Scilit: